title: Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
abstract: Imatinib mesylate (IM) represents the first-line treatment of patients with chronic myeloid leukemia (CLM) or gastrointestinal stromal tumor (GIST). It presents several side effects. However, less than 10% are nonhematologic including nausea, vomiting, diarrhea, muscle cramps, and cutaneous reactions. The aim of our study was to identify data regarding IM cutaneous adverse effects (AEs) to improve the clinical diagnosis and management of the more frequent side effects. Skin examination should be done before and during IM treatment so that AEs can be diagnosed and treated early with less impact on chemotherapy treatments and on the quality of life of the patient.
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paolino
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Didona
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: Clerico
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Corsetti
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Ambrifi
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy; University Magna Graecia, Catanzaro, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: Bottoni
authors.affiliation: Dermatology Clinic, Department of Internal Medicine and Medical Specialties, University of Rome, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002280:Basal Cell Carcinoma / Q000139:chemically induced; D012628:Dermatitis, Seborrheic / Q000139:chemically induced; D003881:Dermatomycoses / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology*; D004485:Eczema / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D018219:Histiocytoma, Benign Fibrous / Q000139:chemically induced; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects*; D055623:Keratosis, Actinic / Q000139:chemically induced; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced; D009916:Orbital Diseases / Q000139:chemically induced; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced; D011565:Psoriasis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate